It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery delivers sensitive, reproducible LC-MS/MS methods tailored to diverse compound classes and biological matrices. From early discovery through non-GLP preclinical studies, we provide accurate quantification of parent compounds, metabolites, and biomarkers, helping your move from insight to outcome faster.
At Sygnature Discovery, we provide end-to-end bioanalytical support that combines analytical method development and quantitative bioanalysis to accelerate your drug discovery programs.
Our approach is built on scientific rigor, flexibility, and collaboration ensuring every method is tailored to your compound properties and study design.
Analytical Method Development
Expertise in Complex Matrices We design robust, transferable bioanalytical methods for challenging biological matrices- including blood, plasma, urine, bile, and tissues- ensuring cross-species applicability and reliable in vitro–in vivo extrapolation. Techniques such as protein precipitation (PPT), solid phase extraction (SPE), and supported-liquid extraction (SLE) ensure that only scientifically rigorous and reproducible methods are employed.
Predefined Acceptance Criteria Every assay meets strict standards for linearity, accuracy, precision, matrix effects, and carryover, aligned with regulatory guidelines.
Collaborative Approach Our scientists work as an extension of your team, aligning method development with compound properties and study design to accelerate timelines and deliver decision-enabling data.
Quantitative Bioanalysis
Our independent DMPK consultancy provides unbiased scientific oversight and strategic input at key decision points. We deliver expert reviews of discovery-stage projects and research proposals to ensure that DMPK considerations are rigorously evaluated before experimental investment. These assessments identify potential ADME and PK risks early and lead to data-driven recommendations that strengthen project robustness and translational potential.
Reliable Pharmacokinetic Assessment
Foundation for PK Studies: Robust bioanalysis underpins accurate in vivo pharmacokinetic evaluation.
Advanced Platforms: UPLC-MS/MS ensures high sensitivity and selectivity.
Comprehensive Quantification: Parent compounds, metabolites, and biomarkers measured across plasma, blood, urine, and tissues.
Specialized Expertise: Handling small molecules, peptides, large analytes, and highly polar compounds, applying HILIC where needed.
Operational Efficiency: Rapid turnaround without compromising quality- keeping your program on track.
Why Choose Sygnature Discovery for Analytical Method Development and Bioanalysis
Extensive Molecular Expertise: Deep experience across diverse analytes.
Tailored Sample Preparation: PPT, SPE, and SLE applied to complex challenges.
Flexible, High-Performance Instrumentation: Multi-vendor platforms for optimized methods and high-throughput analysis.
Continuity from Discovery to Development: Transferable, scalable methods supporting early discovery through non-GLP preclinical studies.
Collaborative and Agile Execution: Acting as an extension of your team for fast, data-driven decisions.
Bifunctional degraders bind and degrade proteins via ubiquitin ligase, despite breaking bRo5 rules. Translating in vitro DMPK data to in vivo performance remains a challenge. At Sygnature Discovery, we provide tailored assays and expertise to support projects involving these compounds. Read more in the poster.
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
